BRCA2 and prostate carcinoma: The study confirmed the association of the BRCA2 K3326X variant with an increased risk of developing triple-negative breast and serous ovarian cancers irrespective of additional BRCA2 pathogenic variants, while no association with prostate cancer risk was found [12].